Acadia ( ACAD ) shares are jumping higher after providing compelling data from its clinical trial in dementia-related psychosis for its drug pimavanserin. As a result, the shares have climbed to a new all-time high eclipsing its prior highs set in July 2015. The opportunity for Acadia appears ...

ACADIA Pharmaceuticals ( ACAD +16% ) is up on almost double normal volume in reaction to positive results from a Phase 3 clinical trial, HARMONY , evaluating Nuplazid (pimavanserin) for the treatment of dementia-related psychosis, a Breakthrough Therapy-tagged indication. The data were ...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) +102%  as voclosporin successful in late-stage lupus nephritis study. More news on: Aurinia Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., SeaChange International, Inc., Stocks on the move, Read more ...